BCA
IMPL

Berman Capital Advisors’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

Berman Capital Advisors’s Portfolio IMPL Stock Details IMPL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$4K Hold
397
– – ﹤0.01% 1530
2021
Q2 		$3K Buy
+397
New +$4.74K ﹤0.01% 1535

Other funds holding IMPL

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
NVPX
Norwest Venture Partners XIV Palo Alto, California $60.4M AUM 9.56% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Berman Capital Advisors's IMPL Position: Q3 2021 in Review

Berman Capital Advisors held its Impel Pharmaceuticals Inc. Common Stock (IMPL) position steady in Q3 2021 at 397 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #1530.

Berman Capital Advisors first reported a position in IMPL in Q2 2021 and has held it in 2 quarters since. 44 funds tracked by Wall St. Rank hold IMPL as of Q3 2021.

  • Berman Capital Advisors held 397 shares of Impel Pharmaceuticals Inc. Common Stock worth $4K as of Q3 2021.
  • Berman Capital Advisors left its Impel Pharmaceuticals Inc. Common Stock share count unchanged in Q3 2021.
  • Impel Pharmaceuticals Inc. Common Stock made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1530 holding.
  • Berman Capital Advisors first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q2 2021 and has held it in 2 quarters since.
  • 44 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.